Drug Search Results
More Filters [+]

SHR-1909

Alternative Names: shr-1909, shr 1909, shr1909
Latest Update: 2022-03-02
Latest Update Note: Clinical Trial Update

Product Description

For Advanced Malignant Cancer (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05162469)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Fusion Protein

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Shanghai Hengrui Pharmaceutical
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for SHR-1909

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CTR20213194

P1

Not yet recruiting

Oncology Solid Tumor Unspecified

None

Recent News Events

Date

Type

Title